ADIL - Adial Pharmaceuticals Inc logo

Adial Pharmaceuticals Inc

ADIL

Adial Pharmaceuticals develops therapeutics for addiction and related disorders, focusing on its lead product, AD04, a serotonin-3 antagonist in Phase 3 trials for alcohol use disorder. It also explores treatments for non-opioid pain and other diseases.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$2today

Score Overview

1 Year
Scoreโ€”
Net Growth2.59%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth59.99%
Net Trend80%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth33.19%
Net Trend63%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Adial Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ADIL does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 3.92โ€”
1 Year2025-10-23
$ 8.97-56.31%
5 Years2021-10-22
$ 2.17K-99.82%
All Time2018-07-30
$ 2.5K-99.84%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 7M$ 4M
2025$ 0.00-$ 7M$ 5M
2024$ 0.00-$ 13M$ 3M
2023$ 0.00-$ 7M$ 2M
2022$ 0.00-$ 12M$ 4M
2021$ 0.00-$ 19M$ 6M
2020$ 0.00-$ 10M$ 4M
2019$ 0.00-$ 8M$ 6M
IPO2018$ 0.00-$ 11M$ 3M
ADIL - Adial Pharmaceuticals Inc logo

Adial Pharmaceuticals Inc fundamental performance

Across Adial Pharmaceuticals Inc's full reported history, from 2018 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 11M to -$ 7M. Revenue increased in 0% of the years measured; net income in 63%.

Membership

Explore ADIL with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies